title: Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
abstract: Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom mn.ramasamy@doctors.org.uk.
authors: Maheshi N
authors: MN
authors: Ramasamy
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
authors: Elizabeth A
authors: EA
authors: Clutterbuck
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
authors: Kathryn
authors: K
authors: Haworth
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
authors: Jaclyn
authors: J
authors: Bowman
authors: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.
authors: Omar
authors: O
authors: Omar
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
authors: Amber J
authors: AJ
authors: Thompson
authors: Department of Paediatrics, Children's Hospital of Geneva, Geneva, Switzerland.
authors: Geraldine
authors: G
authors: Blanchard-Rohner
authors: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.
authors: Ly-Mee
authors: LM
authors: Yu
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
authors: Matthew D
authors: MD
authors: Snape
authors: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
authors: Andrew J
authors: AJ
authors: Pollard
mesh_terms: D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008585:Meningitis, Meningococcal / Q000276:immunology* / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology*; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D006113:United Kingdom; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000276:immunology*; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; C043226:meningococcal group A polysaccharide; C037676:meningococcal group C polysaccharide; C410218:serogroup C meningococcal conjugate vaccine